TRICARE Prior Authorization Request Form for zuranolone (**Zurzuvae**)



USFHP Pharmacy Prior Authorization Form

7231 Parkway Drive, Suite 100, Hanover, MD 21076

FAX Completed Form and Applicable Progress Notes to: (410) 424-4037

To be completed by Requesting provider				
Drug Name:	Strength:			
Dosage/Frequency (SIG):	Duration of Therapy:			

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

	tiioiizati	on expires after 1 year.					
Step	Please complete patient and physician information (please print):						
1	Patient Name: Pl		ysician Name:				
	Addres	es:	Address:				
	Sponso	or ID #	Phone #:				
	Date of Birth:		Secure Fax #:				
Step 2	Please complete the clinical assessment:						
	Has the patient received this medication under the TRICARE benefit in the last 6 months? Please choose "No" if the patient did not previously have a TRICARE approved PA for Zurzuvae.	☐ Yes	□ No				
		Proceed to question 2	Proceed to question 3				
	Has the patient had a positive response to therapy and the risks of continued therapy do not outweigh the benefits?	□ Yes	□ No				
		Sign and date below	STOP				
	· ·			Coverage not approved			
	3.	Is the patient 18 years of age or older?	□ Yes	□ No			
			Proceed to question 4	STOP			
				Coverage not approved			
	4. Does the patient have postpartum depression (PPD)?	□ Yes	□ No				
		Proceed to question 5	STOP				
		Note: Use for major depressive disorder is not allowed.		Coverage not approved			
	5.	Is the patient 12 months or less postpartum?	☐ Yes	□ No			
			Proceed to question 6	STOP			
				Coverage not approved			

TRICARE Prior Authorization Request Form for zuranolone (Zurzuvae)

	6.	Does the patient have a contraindication to, intolerability to, or has failed a trial of ONE formulary antidepressant medication (note: failure of medication is defined as a minimum treatment duration of 4-6 weeks at maximally tolerated dose)? Examples of formulary antidepressants include: • selective serotonin reuptake inhibitors (SSRIs, for example, citalopram, escitalopram, fluoxetine, paroxetine, sertraline), • serotonin/norepinephrine reuptake inhibitors (SNRIs, for example, venlafaxine, duloxetine; not including milnacipran), • tricyclic antidepressants (TCAs, for example, amitriptyline, desipramine, imipramine, nortriptyline), • mirtazapine, • bupropion, • trazodone immediate-release, • nefazodone, and • monoamine oxidase inhibitors (MAOIs)	☐ Yes Proceed to question 7	□ No STOP Coverage not approved	
	7.	Will the patient use effective contraception during treatment and for one week after the final dose?	☐ Yes Sign and date below	□ No STOP Coverage not approved	
Step 3	I certi	ify the above is true to the best of my knowled	edge. Please sign and o	date: [5 December 2023]	
or Inte	rnal Use	e Only	Duration of Approva	I:month(s)	
Denied:			Authorized By:		
] Incomplete/Other:			PA#:		
ate Faxed to MD:			Date Decision Rendered:		